Design of a superior cytokine antagonist for topical ophthalmic use

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 10, 2013, Pages 3913-3918

  Hou, Jinzhao ^a   Townson, Sharon A ^a   Kovalchin, Joseph T ^a   Masci, Allyson ^a   Kiner, Olga ^a   Shu, Yanqun ^a   King, Bracken M ^a   Schirmer, Emily ^a   Golden, Kathryn ^a   Thomas, Christoph ^a   Garcia, K Christopher ^b   Zarbis Papastoitsis, Gregory ^a   Furfine, Eric S ^a   Barnes, Thomas M ^a  

^a Eleven Biotherapeutics   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTOKINE RECEPTOR ANTAGONIST; EBI 005; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHIMERA; CONTROLLED STUDY; DRUG BINDING; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRY EYE; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; THERMOSTABILITY;

ADMINISTRATION, TOPICAL; AMINO ACID SEQUENCE; ANIMALS; CRYSTALLOGRAPHY, X-RAY; CYTOKINES; DRUG DESIGN; DRUG STABILITY; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; KINETICS; LIGANDS; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; OPHTHALMIC SOLUTIONS; PROTEIN CONFORMATION; RECEPTORS, INTERLEUKIN-1 TYPE I; RECOMBINANT FUSION PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; STATIC ELECTRICITY;

EID: 84874587995     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1217996110     Document Type: Article

References (46)

1. Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117(14):3720-3732.
2. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S (2008) The phenotype of human Th17 cells and their precursors, the cytokines that mediate their differentiation and the role of Th17 cells in inflammation. Int Immunol 20(11):1361-1368.
3. Stritesky GL, Yeh N, Kaplan MH (2008) IL-23 promotes maintenance but not commitment to the Th17 lineage. J Immunol 181(9):5948-5955.
4. Mitroulis I, Skendros P, Ritis K (2010) Targeting IL-1β in disease; the expanding role of NLRP3 inflammasome. Eur J Intern Med 21(3):157-163.
5. Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519-550.
6. Mertens M, Singh JA (2009) Anakinra for rheumatoid arthritis: A systematic review. J Rheumatol 36(6):1118-1125.
7. Preas HL, et al. (1996) Effects of recombinant soluble type I interleukin-1 receptor on human inflammatory responses to endotoxin. Blood 88(7):2465-2472.
8. Hoffman HM, et al. (2008) Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies. Arthritis Rheum 58(8):2443-2452.
9. Amparo F, et al. (2013) Topical interleukin-1 receptor antagonist for treatment of dry eye disease. JAMA Ophthalmol 131: in press.
10. Stern ME, et al. (2010) Autoimmunity at the ocular surface: Pathogenesis and regulation. Mucosal Immunol 3(5):425-442.
11. Stevenson W, Chauhan SK, Dana R (2012) Dry eye disease: An immune-mediated ocular surface disorder. Arch Ophthalmol 130(1):90-100.
12. Solomon A, et al. (2001) Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci 42(10):2283-2292.
13. Zhu L, et al. (2009) Inflammatory cytokine expression on the ocular surface in the Botulium toxin B induced murine dry eye model. Mol Vis 15:250-258.
14. Okanobo A, Chauhan SK, Dastjerdi MH, Kodati S, Dana R (2012) Efficacy of topical blockade of interleukin-1 in experimental dry eye disease.AmJ Ophthalmol 154(1):63-71.
15. Chen Y-T, et al. (2010) Interleukin-1 as a phenotypic immunomodulator in keratinizing squamous metaplasia of the ocular surface in Sjögren's syndrome. Am J Pathol 177(3):1333-1343.
16. Binshtok AM, et al. (2008) Nociceptors are interleukin-1β sensors. J Neurosci 28(52): 14062-14073.
17. Gabay E, Wolf G, Shavit Y, Yirmiya R, Tal M (2011) Chronic blockade of interleukin-1 (IL-1) prevents and attenuates neuropathic pain behavior and spontaneous ectopic neuronal activity following nerve injury. Eur J Pain 15(3):242-248.
18. Sommer C, Petrausch S, Lindenlaub T, Toyka KV (1999) Neutralizing antibodies to interleukin 1-receptor reduce pain associated behavior in mice with experimental neuropathy. Neurosci Lett 270(1):25-28.
19. White FA, Jones KJ (2008) IL-1beta signaling initiates inflammatory hypernociception. Brain Behav Immun 22(7):1014-1015.
20. Jarvinen K (1995) Ocular absorption following topical delivery. Adv Drug Deliv Rev 16: 3-19.
21. Greenfeder SA, et al. (1995) Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J Biol Chem 270(23):13757-13765.
22. Evans RJ, et al. (1995) Mapping receptor binding sites in interleukin (IL)-1 receptor antagonist and IL-1 beta by site-directed mutagenesis: Identification of a single site in IL-1ra and two sites in IL-1 beta. J Biol Chem 270(19):11477-11483.
23. Schreuder H, et al. (1997) A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature 386(6621):194-200.
24. Vigers GPA, Anderson LJ, Caffes P, Brandhuber BJ (1997) Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1β. Nature 386(6621):190-194.
25. Thomas C, Bazan JF, Garcia KC (2012) Structure of the activating IL-1 receptor signaling complex. Nat Struct Mol Biol 19(4):455-457.
26. Wang D, et al. (2010) Structural insights into the assembly and activation of IL-1β with its receptors. Nat Immunol 11(10):905-911.
27. Boraschi D, Bossu P, Macchia G, Ruggiero P, Tagliabue A (1996) Structure-function relationship in the IL-1 family. Front Biosci 1:d270-d308.
28. Niesen FH, Berglund H, Vedadi M (2007) The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc 2(9):2212-2221.
29. Symons JA, Young PR, Duff GW (1995) Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 β precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci USA 92(5):1714-1718.
30. Smith DE, et al. (2003) The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity 18(1):87-96.
31. Arend WP, et al. (1994) Binding of IL-1 α, IL-1 β, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J Immunol 153(10):4766-4774.
32. Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP (1991) Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem 266(16):10331-10336.
33. Mizel SB, Kilian PL, Lewis JC, Paganelli KA, Chizzonite RA (1987) The interleukin 1 receptor: Dynamics of interleukin 1 binding and internalization in T cells and fibroblasts. J Immunol 138(9):2906-2912.
34. Latypov RF, et al. (2007) Biophysical characterization of structural properties and folding of interleukin-1 receptor antagonist. J Mol Biol 368(4):1187-1201.
35. Latypov RF, et al. (2009) Denaturant-dependent conformational changes in a betatrefoil protein: Global and residue-specific aspects of an equilibrium denaturation process. Biochemistry 48(46):10934-10947.
36. Gosavi S, Whitford PC, Jennings PA, Onuchic JN (2008) Extracting function from a beta-trefoil folding motif. Proc Natl Acad Sci USA 105(30):10384-10389.
37. Roy M, Jennings PA (2003) Real-time NMR kinetic studies provide global and residuespecific information on the non-cooperative unfolding of the β-trefoil protein, interleukin- 1β. J Mol Biol 328(3):693-703.
38. Capraro DT, Roy M, Onuchic JN, Gosavi S, Jennings PA (2012) β-Bulge triggers routeswitching on the functional landscape of interleukin-1β. Proc Natl Acad Sci USA 109(5):1490-1493.
39. Raibekas AA, et al. (2005) Anion binding and controlled aggregation of human interleukin- 1 receptor antagonist. Biochemistry 44(29):9871-9879.
40. Gu LC, et al. (1991) Stability of interleukin 1 β (IL-1 β) in aqueous solution: Analytical methods, kinetics, products, and solution formulation implications. Pharm Res 8(4): 485-490.
41. Sims JE (2010) Accessory to inflammation. Nat Immunol 11(10):883-885.
42. Vigers GP, Dripps DJ, Edwards CK, Brandhuber BJ (2000) X-ray crystal structure of a small antagonist peptide bound to interleukin-1 receptor type 1. J Biol Chem 275(47):36927-36933.
43. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276:307-326.
44. McCoy AJ, et al. (2007) Phaser crystallographic software. J Appl Cryst 40(Pt 4):658-674.
45. Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66(Pt 4):486-501.
46. Krissinel E, Henrick K (2007) Inference of macromolecular assemblies from crystalline state. J Mol Biol 372(3):774-797.